CDKN2A and neoplasm: Of note were the complete tumor regressions observed in the YUMM1.7 model, a more clinically relevant murine model that harbors important molecular aberrations observed in human melanoma (including in Braf V600E, and inactivated Cdkn2a and Pten) (39).